Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1793 Target Snapshot

Parathyroid hormone/parathyroid hormone-related peptide receptor · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
46,854Compounds
57Assays
2Approved Drugs
188.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Parathyroid hormone/parathyroid hormone-related peptide receptor shows approved-linked disease relevance led by hypoparathyroidism. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q03431. Start with hypoparathyroidism, then reuse UniProt Q03431 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with hypoparathyroidism, then reuse UniProt Q03431 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 4 linked drugs
Open source guide
Disease program
hypoparathyroidism

Parathyroid hormone/parathyroid hormone-related peptide receptor shows approved-linked disease relevance led by hypoparathyroidism. 5 more disease programs remain visible in the same review block. 4 linked drugs remain visible in the same block.

Start review with hypoparathyroidism because it currently carries approved-linked support. Linked drugs include PALOPEGTERIPARATIDE, PARATHYROID HORMONE, TERIPARATIDE, TERIPARATIDE ACETATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 4 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Parathyroid hormone/parathyroid hormone-related peptide receptor as ChEMBL target CHEMBL1793, mapped to UniProt Q03431. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Parathyroid hormone/parathyroid hormone-related peptide receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1793
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q03431
Parathyroid hormone/parathyroid hormone-related peptide receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Parathyroid hormone/parathyroid hormone-related peptide receptor is the right protein anchor across sources, using UniProt Q03431 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why hypoparathyroidism is currently framed as approved-linked support. It currently carries 4 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameParathyroid hormone/parathyroid hormone-related peptide receptor
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ03431
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelParathyroid hormone/parathyroid hormone-related peptide receptor
UniProt AccessionQ03431
Component TypeProtein
Sequence Length593 aa

Parathyroid hormone/parathyroid hormone-related peptide receptor

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Parathyroid hormone/parathyroid hormone-related peptide receptor, mapped to UniProt Q03431. Sequence length is 593 aa.

Mapped IDQ03431
Review nameParathyroid hormone/parathyroid hormone-related peptide receptor
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Parathyroid hormone/parathyroid hormone-related peptide receptor shows approved-linked disease relevance led by hypoparathyroidism. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
hypoparathyroidism
4 linked drugs · 4 direct · 4 efficacy
Linked drugPALOPEGTERIPARATIDE
Linked drugPARATHYROID HORMONE
Linked drugTERIPARATIDE
Linked drugTERIPARATIDE ACETATE
Approved-linked Approved
osteoporosis
4 linked drugs · 4 direct · 4 efficacy
Linked drugABALOPARATIDE
Linked drugPARATHYROID HORMONE
Linked drugTERIPARATIDE
Linked drugTERIPARATIDE ACETATE
Approved-linked Approved
postmenopausal osteoporosis
4 linked drugs · 4 direct · 4 efficacy
Linked drugABALOPARATIDE
Linked drugPARATHYROID HORMONE
Linked drugTERIPARATIDE
Linked drugTERIPARATIDE ACETATE
Approved-linked Approved
Hypocalcemia
2 linked drugs · 2 direct · 2 efficacy
Linked drugPARATHYROID HORMONE
Linked drugTERIPARATIDE
Late clinical Phase III
bone fracture
2 linked drugs · 2 direct · 2 efficacy
Linked drugABALOPARATIDE
Linked drugTERIPARATIDE
Late clinical Phase III
hip fracture
2 linked drugs · 2 direct · 2 efficacy
Linked drugOSTABOLIN-C
Linked drugTERIPARATIDE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with hypoparathyroidism because it currently carries approved-linked support. Linked drugs include PALOPEGTERIPARATIDE, PARATHYROID HORMONE, TERIPARATIDE, TERIPARATIDE ACETATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasehypoparathyroidism
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Approved
1
Phase I
Assay Mix

Activity Type Distribution

IC5063.0
KI26.0
EC5091.0
KD8.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL526530 10.22 EC50 0.06 Preclinical
CHEMBL4098420 10.22 EC50 0.06 Preclinical
CHEMBL4080397 10.15 EC50 0.07 Preclinical
CHEMBL4060034 10.1 EC50 0.08 Preclinical
CHEMBL525610 10.1 IC50 0.08 Approved
CHEMBL4090619 9.92 EC50 0.12 Preclinical
CHEMBL4106296 9.89 EC50 0.13 Preclinical
CHEMBL4088173 9.85 EC50 0.14 Preclinical
CHEMBL506126 9.82 EC50 0.15 Preclinical
CHEMBL4061182 9.82 EC50 0.15 Preclinical
Distribution

pChEMBL Value Distribution

17
5.0
11
5.5
16
6.0
13
6.5
15
7.0
15
7.5
18
8.0
15
8.5
17
9.0
13
9.5
pChEMBL
Approved Drugs

Approved Drugs

TERIPARATIDE
CHEMBL525610
Approved 2002
Properties Compare Identifier
Assay Landscape

Assay Landscape

59
Total Assays
118
Tested Compounds
2
Assay Types
Functional — 42 assays, 118 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 39 117 7.2
assay format 2 0 —
single protein format 1 1 9.9
Binding — 17 assays, 40 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 9 38 7.2
single protein format 5 0 —
assay format 3 2 7.1

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine